Targets › KAT6B
4 programs from 4 companies in 6 trials: 4 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Hematology; next expected readout Dec 2026.
Histone acetyltransferase which may be involved in both positive and negative regulation of transcription. Required for RUNX2-dependent transcriptional activation. (UniProt, Q8WYB5)
Open in Phaseline: the race on KAT6B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | PF-07248144 KAT6 inhibitor | KAT6A, KAT6B | Phase 3 | Breast Cancer; Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Jul 2027 |
| Medical College of Wisconsin | Iadademstat KAT6A/KAT6B histone acetyltransferase inhibitor | KAT6A, KAT6B | Phase 1 | Myelodysplastic Syndromes | Dec 2026 |
| Olema Pharmaceuticals | OP-3136 Selective inhibitor of KAT6A and KAT6B | KAT6A, KAT6B | Phase 1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | May 2027 |
| BeOne Medicines | BG-75202 KAT6A/B inhibitor | KAT6A, KAT6B | Phase 1 | Myeloid Malignancy; Breast Cancer | Sep 2028 |
Breast Cancer (2) Myelodysplastic Syndromes (1) Locally Advanced or Metastatic ER+ HER2- Breast Cancer (1) Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) (1) Myeloid Malignancy (1)
small molecule (3), mixed (1)
Medical College of Wisconsin (1) Pfizer (1) Olema Pharmaceuticals (1) BeOne Medicines (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.